Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Barber

Orthopaedic Surgery Mobile, AL Medical Doctor

NPI 1346338647 CMS profile 106612

3610 Springhill Memorial Dr N, Mobile, AL 36608

Open in the dashboard

General payments

$158,128

195 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$51,300

4 holdings reported · through program year 2025

Research they led as principal investigator

$18,400 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Matthew Barber of Mobile, AL is reported in the CMS Open Payments database as having received $158,128 across 195 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,400 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $51,300 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,148 34
2024 General $36,731 31
2023 General $29,505 27
2022 General $23,535 39
2021 General $7,005 20
2020 General $3,311 19
2019 General $15,894 25
2025 Ownership $13,800 1
2024 Ownership $12,500 1
2023 Ownership $12,500 1
2022 Ownership $12,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Barber
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Matthew Barber were reported at $42,148. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Matthew Barber Orthopaedic Surgery median Middle half National median
2019 $15,894 $644 $140–$2,844 $163
2020 $3,311 $312 $75–$1,860 $114
2021 $7,005 $520 $117–$2,495 $132
2022 $23,535 $598 $128–$2,731 $149
2023 $29,505 $461 $128–$2,264 $160
2024 $36,731 $497 $134–$2,475 $164
2025 $42,148 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intellijoint Surgical Inc. $51,650 5 payments
  2. Uoc USA Inc $31,514 24 payments
  3. Ortho Development Corporation $27,602 40 payments
  4. Think Surgical, Inc. $16,496 12 payments
  5. Conformis, Inc. $14,188 19 payments
  6. Heron Therapeutics, Inc. $7,183 5 payments
  7. Globus Medical, Inc. $3,672 11 payments
  8. Medacta USA, Inc. $2,998 12 payments
  9. Smith+Nephew, Inc. $1,053 16 payments
  10. restor3d, inc. $454 3 payments
  11. Other $1,318 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $103,013 29 payments
  2. Royalty or License $18,815 24 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,118 7 payments
  4. Travel and Lodging $14,042 30 payments
  5. Food and Beverage $5,140 105 payments
Products named General payments · program years 2019–2025
  1. Intelljoint $22,750 1 payment
  2. BKS TriMax $17,853 18 payments
  3. Intellijoint HIP 628184001721 $15,000 1 payment
  4. Tsolution One Surgical System $14,398 9 payments
  5. Intellijoint HIP Orthopedics $13,900 3 payments
  6. U2, PSA, U-Star II $10,763 1 payment
  7. U2, PSI $7,875 2 payments
  8. ZYNRELEF $7,163 4 payments
  9. PSI $7,082 3 payments
  10. iTotal $5,600 3 payments
  11. Other $35,871 163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,687

Median for Orthopedic Surgery: 203

Drug cost

$34,215

Median for Orthopedic Surgery: $1,433

Branded share of claims

23.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 427 $9,319
Tranexamic Acid Generic 144 $8,323
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 421 $5,110
Cefadroxil Generic 330 $2,396
Tramadol Hcl Generic 437 $2,218
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 132 $1,609
Diclofenac Sodium Generic 74 $1,352
Cephalexin Generic 189 $855
Methylprednisolone Generic 61 $505
Meloxicam Generic 116 $478

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$162,351

Of which drugs: $584

Medicare patients

311

Average age 74

Services billed

1,518

209 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 30%
Depression 25%
Chronic kidney disease 23%
Osteoporosis 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 368 $266

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APONVIE
  • Heron Therapeutics, Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record